你是 stock-analyst v20 DD 的證據採集子 agent。標的：BSX。
你負責下列 1 個覆蓋軸，逐軸獨立查證，**本軸最多 4 次 WebSearch**（每一類題目一次），查不到就記 none，不要一直挖。

[reg_tariff_export] 關稅／出口管制
Q: 本標的的產品、供應鏈或客戶是否暴露在關稅或出口管制變動下？
  - BSX Boston Scientific tariff section 232 2026
  - Boston Scientific export control OR entity list Medical Devices 2026
  - BSX Boston Scientific China tariff OR trade restriction 2026
  - Medical Devices tariff exposure supply chain 2026


## 規則（嚴格遵守，違反視為無效輸出）
1. **只回 sourced claim**：每條 finding 必須有可查證的 source（URL 或明確可搜尋到的來源名＋標題）與 as_of（該資訊的發布/生效日期，非你查詢的日期）。
2. **查不到就 status="none"**，並列出你實際下過的 queries_run（至少 1 條，需與你實際搜尋詞一致，不得事後編造）。軸清單裡的 `queries` 是起點不是配額，同一次搜尋的來源可同時支撐多個軸。**不得因為查無所獲就用訓練知識/常識填 claim。**
3. **三種狀態不得混用**：found＝有 sourced claim；none＝軸適用於本標的業態、但搜尋查無來源；not_applicable＝該軸對本標的業態根本不成立（例：銀行沒有「最大客戶導入第二供應商」、零售商的客戶是終端消費者）。**軸對此業態不適用時回 not_applicable 並在 note 寫理由，不要回 none。**只有軸物件標 na_allowed=true 才可回 not_applicable，沒標的軸只能 found 或 none；拿不準是否適用就當適用、照常搜尋，不要用 not_applicable 省搜尋。
4. **不臆測、不外推**：claim 只寫你實際找到的事實，不要自己推論「這意味著」，那是判斷層的工作。
5. direction 欄：這條 finding 對本標的是正面(+)／中性(0)／負面(-)，僅標事實方向，不要寫成裁決語。
6. affects 欄：這條 finding 影響哪些判斷面（可填 moat_trend／thesis.H／thesis.R／decision_inputs.bear／valuation／triggers 等，可複選）。
7. **現價一律引 `numbers.price_at_dd`／`price_as_of`，不得自行寫「現價」數字**：市值、距 52 週高低點 %、目標價 vs 現價，一律引用該欄，不從聚合站另抓現價字面數字。
8. **原始證據與解讀分開存**：每條 finding 另填三欄——`url`（實際讀到的網址，沒有就填 null）、`excerpt`（從該來源**逐字複製**、支撐 claim 的原文，≤300 字，不得改寫或翻譯）、`excerpt_from`（`snippet`＝搜尋摘要／`page`＝WebFetch 讀到的頁面）。`claim` 是你對原文的精簡轉述；`excerpt` 是證據本身。找不到可逐字複製的原文就填 null，不要自己寫一句當原文。

## 程式已抓好的一手文件摘錄（本軸）
以下為程式抓取的一手文件摘錄，可直接逐字引用（附 url 與 as_of）：
- 引用時 finding 的 `url`、`as_of` 照該則標示填；`source` 寫「來源＋文件」；`excerpt` 從「<<<」「>>>」之間**逐字複製**（≤300 字，取最能支撐 claim 的連續一段，不改寫、不翻譯）；`excerpt_from` 填 `"page"`。
- 一手清單顯示沒有某類事件時（例如「標題含關鍵字者 0 則」），可據此寫一條「經查一手紀錄無此類事件」的 finding（status=found、direction=`"0"`），excerpt 用清單本身那一句統計；不要因為沒找到事件就標 none。
- 這些摘錄不算你的搜尋：`queries_run` 只記你自己實際下過的搜尋；摘錄仍可另外搜尋補充，但不必為了湊證據重搜摘錄已涵蓋的內容。
- 摘錄與本軸問題無關或不足以回答時，照常搜尋；仍查不到才記 none。

[1] 來源：SEC EDGAR｜文件：10-K（FY2025，申報 2026-02-17）｜章節：Item 1. Business｜url：https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/bsx-20251231.htm｜as_of：2026-02-17
<<<
Regulatory Environment As a global company, we are governed by federal, state, local and international laws of general applicability relating to, among other things, employment, labor, privacy and data protection, governance and securities, anti-corruption, fraud and abuse (including anti-kickback and false claims laws), competition, trade and export controls. In general, the scope and complexity of regulations applicable to our business has increased over time. We anticipate that governmental authorities will continue to scrutinize our industry closely and that additional regulation may increase compliance and legal costs. Any adverse regulatory actions or exposure to litigation could have an adverse effect on our business, results of operations or financial condition.
>>>

[2] 來源：SEC EDGAR｜文件：10-K（FY2025，申報 2026-02-17）｜章節：Item 1A. Risk Factors｜url：https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/bsx-20251231.htm｜as_of：2026-02-17
<<<
The global macroeconomic environment has continued to experience challenging conditions and uncertainty, including with respect to inflation, interest rates, monetary policy, exchange rates, tariff and trade policies and geopolitical developments, which could adversely impact our business, financial condition, cash flows and results of operations. If there were a general economic slowdown or recession, we may experience decreased customer spending or demand for our products and services, and our customers’ ability to pay for our products on a timely basis, or at all, may be impacted. The same economic conditions could also adversely affect our third-party vendors, including those that we utilize in our supply-chain and manufacturing operations, which may lead to a reduction or interruption in the supply of materials and components used in manufacturing our products or increase the price of such materials or components, as well as the distributors and dealers who offer our products in certain countries and markets. Continued inflationary pressure may also increase certain operational costs, including due to 14 wage increases, or increases in the cost of materials or components.…

International net sales accounted for 36 percent of our global net sales in 2025. An important part of our strategy is to continue pursuing growth opportunities in net sales and market share outside of the U.S. by expanding global presence, including in Emerging Markets. Our international operations are subject to a number of market, business and financial risks and uncertainties, including those related to our use of channel partners, go-to-market strategies, geopolitical and economic instability, foreign currency exchange and interest rate fluctuations, competitive product offerings, local changes in health care financing and payment systems and health care delivery systems, local product preferences and requirements, including preferences for local manufacturers, trade protection measures, including tariffs and other barriers to market participation, workforce instability, weaker intellectual property protection in certain countries than exists in the U.S. and longer accounts receivable cycles. Such risks and uncertainties may adversely impact our ability to implement our growth strategy in these markets and, as a result, our sales growth, market share and operating profits from our international operations may be adversely affected.

In addition, our international operations are subject to other established and developing U.S. and foreign legal and regulatory requirements, including FCPA and/or similar laws in other countries, and U.S. and foreign import and export controls and licensing requirements, trade protection and embargo measures and customs laws. Global businesses, including those in the medical device industry, are facing increasing scrutiny of, and heightened enforcement efforts with respect to, their 15 international operations. Any alleged or actual failure to comply with legal and regulatory requirements may subject us to government scrutiny, civil and/or criminal proceedings, sanctions, fines and penalties, or reputational harm which may have a material adverse effect on our international operations, financial condition, results of operations and/or liquidity.

There continues to exist significant uncertainty regarding potential shifts in trade policies, tariffs and other trade protection measures, and the reaction of countries thereto, or changes to international trade agreements, which could have a material adverse effect on our operations, including our ability to source and manufacture products in a timely and cost effective manner, financial condition, results of operations and/or liquidity. Legislation aimed at boosting competitiveness of U.S. businesses may have unintended negative effects on our business. We may also face greater competition in China, among other countries, from domestic medical device companies that may benefit from their status as local manufacturers and suppliers.

Geopolitical developments related to ongoing global conflicts and tensions are sources of uncertainty and risk, and may cause disruptions to global or regional markets, supply chains or operations in applicable regions, including those related to the Russia/Ukraine war, tension in the Taiwan strait, and conflicts in the Middle East. Sanctions and export restrictions may continue to proliferate, leading to greater uncertainty in emerging and growth markets. Notably the Russia/Ukraine war has continued to create barriers to doing business in Russia and in parts of Eastern Europe and conflicts in the Middle East have disrupted operations of companies doing business in the region, including in Israel. Any significant changes in the political, economic, financial, competitive, legal and regulatory or reimbursement conditions where we conduct, or plan to expand, our international operations may have a material impact on our business, financial condition or results of operations.

The medical devices we design, develop, manufacture and market are subject to rigorous regulation by the FDA and numerous other federal, state and foreign governmental authorities. These authorities continue to closely scrutinize our industry, including for compliance with the U.S. Anti-Kickback Statute, False Claims Act, Physician Payment Sunshine Act and other health care-related laws, as well as FCPA, competition and U.S. and foreign export control, trade embargo and customs laws, as well as similar laws in other jurisdictions.

We are subject to income taxes as well as non-income based taxes, tariffs, and duties in the U.S. and numerous foreign jurisdictions. Tax laws and regulations could change on a prospective or retroactive basis, and any such changes could have a material adverse effect on our financial condition and results of operations. Following the issuance of any new law or regulation, interpretations are made by the Company, using any regulatory guidance and judicial interpretations issued after the 23 law change. The Company's application of such tax laws, before and after any guidance or interpretations are issued, or in the absence of such guidance or interpretations, may have a material impact on our financial condition and results of operations.

We are subject to certain U.S. tariffs that are currently subject to legal challenge before the U.S. Supreme Court. The timing and outcome of this litigation are uncertain, and the Court’s decision could result in the modification, invalidation, or continuation of such tariffs. Any modification of existing tariffs, or the introduction of new U.S. tariffs under alternative authorities, on imports from the countries where we do business for an extended period and without specific exemptions for our products, and any reciprocal tariffs or other reactions by other countries thereto, could have a material adverse impact on our financial condition, results of operations and cash flows. In addition, while we have paid tariffs that could potentially be subject to refund depending on the outcome of the litigation, there can be no assurance that any such refund would be realized or, if realized, the timing thereof. Any of these developments could have a material adverse effect on our financial condition, results of operations and cash flow.
>>>

[3] 來源：SEC EDGAR｜文件：10-K（FY2025，申報 2026-02-17）｜章節：Item 7. MD&A｜url：https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/bsx-20251231.htm｜as_of：2026-02-17
<<<
Macroeconomic Environment As a global developer, manufacturer and marketer of medical devices, our business is subject to local and international macroeconomic trends as well as geopolitical factors. Continued uncertainty around inflationary pressures, interest rates, foreign currency fluctuations, global trade policies and changes in tax laws, as well as actions by governments in response thereto, could create economic challenges which could negatively impact our business and results of operations. There continues to be significant uncertainty in the tariff environment and with respect to global trade policies, including changing tariff rates, tariff imposition delays, and the potential for reciprocal restrictive trade policies by the U.S. or other governments around the world. We continue to anticipate incurring incremental costs under the current schedule of tariffs on U.S. imports announced by the U.S. government, as well as any potential increases in tariffs introduced by China on U.S. manufactured products. While the U.S. and other governments continue negotiations on such measures, these and any further tariff increases on our products by the U.S., China or any other country or region, as well as sanctions or other measures that restrict international trade, could have a material adverse impact on our business operations and results. We continue to monitor the situation while exploring opportunities to mitigate the impacts of such tariffs.…
>>>


## 回傳格式（嚴格 JSON 契約，不得夾雜其他文字；一次 Write）
```json
{
  "coverage": {
    "<axis_id>": {
      "status": "found|none|not_applicable",
      "queries_run": ["...", "..."],
      "findings": [
        {"claim": "...", "source": "...", "url": "https://...", "excerpt": "逐字原文…", "excerpt_from": "snippet|page", "as_of": "YYYY-MM-DD", "direction": "+|0|-", "affects": ["moat_trend"]}
      ],
      "note": "",
      "clues": [
        {"claim": "...", "source": "...", "url": "https://...", "as_of": "YYYY-MM-DD", "direction": "+|0|-", "affects": ["moat_trend"], "match_terms": ["預期原文逐字出現的字串", "..."]}
      ]
    }
  }
}
```

`clues` 選填、每軸一個陣列，沒有就整個欄位省略。只在你**找到有網址的線索、但沒讀到頁面而拿不到可逐字複製的原文**時放；程式會打開該網址，在全文裡找 `match_terms` 同時出現的一段原文，找到就升級成帶原文的 finding；找不到（或頁面打不開）就照 `excerpt_from: "snippet"`、`excerpt: null` 的 finding 保留，並標為未核原文。
- 只有 clues、findings 是空的時，`status` 填 `none`（程式核實到原文後會自動改成 `found`）。
- `url` 必須是你在搜尋結果裡實際看到的網址；不得編造、不得猜網址、不得填網站首頁。沒有網址的線索不要放（寫進 note）。已經寫在 findings 的網址不要重複放。
- `match_terms` 放 2～5 個預期原文會逐字出現的字串：金額、比例、專有名詞、引號裡的關鍵詞。照原文可能的寫法填，不要改寫或翻譯；不要放公司名、代號、年份或「營收」「公司」這類到處都有的詞。
- 其餘欄位（`claim`、`source`、`as_of`、`direction`、`affects`）規則同 findings；`as_of` 填你推估的文章發布日，程式讀到頁面發布日會以頁面為準。

寫入路徑：`/Users/ivanchang/financial-analysis-bot/.dd_build/runs/BSX_20261103/parts/axes_6.json`（用 Write 工具寫一次，不要分次 Edit）。

## 輪次紀律
你只有 WebSearch、WebFetch、Write 三個工具，沒有 Bash。**寫完 part 檔就停止**，不要自己驗證、不要重讀、不要回報長文。驗證由程式做；缺欄程式會把該軸記成缺口，不會叫你重寫。
搜尋：本軸最多 4 次；WebFetch 只在搜尋摘要不足以寫出 as_of 與 claim 時才用，每軸最多 2 次。

回報 ≤50 字：完成幾軸、found/none 各幾軸。
